Celgene Corp (CELG)

klip1 (< 20) Submitted: 8/23/06 11:14 PM : Start Price: $41.87 CELG Score: 53.08

CELG is a tranformational biotech company that now has 2 successful hemotological cancer drugs on the market: Revlimid and Thalomid. CELG has had an impressive run over the past 5 years but is just now showing explosive earnings growth in conjunction w/this year's launch of Revlimid. Of particlular note, CELG is expecting EU approval for Revlimid within the next 6 months and has said Revlimid shows particular promise for other indications besides multiple myeloma and MDS. It also has several other "imid" drugs in development that should greatly reward shareholders of this terrific company for years to come!

Report this Post Replies: 0 | Reply